The impact of the COVID-19 pandemic on frail older people ageing in place alone in two Italian cities: Functional limitations, care arrangements and available services.

Publication date: Mar 15, 2024

The study aimed to explore and compare effects of lockdown, due to the COVID-19 pandemic in 2020, on frail older people living alone at home in Brescia and Ancona, two urban cities located respectively in Northern and Central Italy. This country was the Western epicenter of the first wave of the pandemic (February-May 2020), which affected the two cities differently as for infections, with a more severe impact on the former. A follow-up study of the IN-AGE research project (2019) was carried out in July-September 2020, by means of telephone interviews, involving 41 respondents. Semi-structured questions focused on the effects of the first wave of the pandemic on their mobility and functional limitations, available care arrangements, and access to health services. The lockdown and social distancing measures overall negatively impacted on frail older people living alone, to a different extent in Ancona and Brescia, with a better resilience of home care services in Brescia, and a greater support from the family in Ancona, where however major problems in accessing health services also emerged. Even though the study was exploratory only, with a small sample that cannot be considered as representative of the population, and despite differences between the two cities, findings overall suggested that enhancing home care services, and supporting older people in accessing health services, could allow ageing in place, especially in emergency times.

Open Access PDF

Concepts Keywords
Ageing Ageing
Italian Ancona
July Arrangements
Telephone Brescia


Type Source Name
disease MESH COVID-19 pandemic
disease IDO country
disease MESH infections
disease VO age
drug DRUGBANK Tropicamide
disease VO population
disease MESH emergency
drug DRUGBANK Serine
pathway REACTOME Reproduction
disease MESH syndrome
drug DRUGBANK Iron
disease MESH retirement
disease VO effectiveness
disease VO effective
drug DRUGBANK Trestolone
disease IDO infection
disease VO vaccine
disease VO vaccinated
disease VO immunized
disease MESH death
disease VO organization
disease MESH unemployment
disease MESH education levels
drug DRUGBANK Pidolic Acid
disease MESH cognitive impairment
disease MESH loneliness
disease IDO object
disease VO protocol
disease VO study design
drug DRUGBANK Polyethylene glycol
disease VO frequency
disease VO USA
disease MESH Marital status
drug DRUGBANK Aspartame
disease IDO quality
disease MESH aids
drug DRUGBANK Isoxaflutole
disease MESH dementia
disease VO LACK
disease MESH chronic conditions
drug DRUGBANK L-Citrulline
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Coenzyme M
disease VO time
disease VO report
disease VO Iss
drug DRUGBANK L-Leucine
drug DRUGBANK Alpha-1-proteinase inhibitor
drug DRUGBANK Nonoxynol-9
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Trimebutine

Original Article

(Visited 1 times, 1 visits today)